TG Therapeutics Inc
TG Therapeutics Inc logo
TGTX

TG Therapeutics Inc (TGTX)

$8.779.35%

Market is closed
– opens on 8 PM, 05 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$7.7
Day's Range
$8.795
$3.48
52-Week Range
$20.69
1 month return50.17%
3 month return50.69%
1 year return46.2%
5 year return7.61%

Company Information

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQTM (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development.
OrganizationTG Therapeutics Inc
Employees186
CEOMr. Michael S. Weiss Esq.
IndustryHealth Technology

Analyst Recommendation

based on 8 analysts ratings

Buy
87%
Buy
0%
Hold
12%
Sell

Based on 8 Wall street analysts offering stock ratings for TG Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 100.23%

Current

$8.77

Target

$17.56

Recommendation Trend

Based on 8 analyst

Current1M Ago3M Ago
Buy
7
12
12
Hold
0
1
1
Sell
1
2
2
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
1.2B
Book Value
$0.75
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.46
PEG Ratio
0.0
Wall Street Target Price
17.56

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
11.54
Enterprise Value
1.1B
Enterprise Value/Revenue
212.12
Enterprise Value/Ebitda
-4.64

Technicals

Beta
2.12
50 Day MA
6.48
200 Day MA
6.96

Institutional Holdings

Vanguard Group Inc

10.14%

State Street Corporation

8.08%

FMR Inc

5.54%

Maverick Capital Ltd

4.64%

Millennium Management LLC

3.41%

Wellington Management Company LLP

3.04%

Discover more

Frequently Asked Questions

What is TG Therapeutics Inc share price today?

Can Indians buy TG Therapeutics Inc shares?

How can I buy TG Therapeutics Inc shares from India?

Can Fractional shares of TG Therapeutics Inc be purchased?

What are the documents required to start investing in TG Therapeutics Inc stocks?

What are today’s High and Low prices of TG Therapeutics Inc?

What are today’s traded volumes of TG Therapeutics Inc?

What is today’s market capitalisation of TG Therapeutics Inc?

What is the 52 Week High and Low Range of TG Therapeutics Inc?

How much percentage TG Therapeutics Inc is down from its 52 Week High?

How much percentage TG Therapeutics Inc is up from its 52 Week low?

What are the historical returns of TG Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of TG Therapeutics Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*